These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 31434293)

  • 1. Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome.
    Di Marzo V; Silvestri C
    Nutrients; 2019 Aug; 11(8):. PubMed ID: 31434293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
.
    Di Marzo V
    Dialogues Clin Neurosci; 2020 Sep; 22(3):259-269. PubMed ID: 33162769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gut microbiome, endocannabinoids and metabolic disorders.
    Iannotti FA; Di Marzo V
    J Endocrinol; 2021 Feb; 248(2):R83-R97. PubMed ID: 33337346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the Endocannabinoidome in Human and Mouse Atherosclerosis.
    Piscitelli F; Silvestri C
    Curr Pharm Des; 2019; 25(29):3147-3164. PubMed ID: 31448709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis.
    Abolghasemi A; Manca C; Iannotti FA; Shen M; Leblanc N; Lacroix S; Martin C; Flamand N; Di Marzo V; Silvestri C
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of selenium on the intestinal microbiome-eCBome axis in the context of diet-related metabolic health in mice.
    Guevara Agudelo FA; Leblanc N; Bourdeau-Julien I; St-Arnaud G; Lacroix S; Martin C; Flamand N; Veilleux A; Di Marzo V; Raymond F
    Front Immunol; 2022; 13():1028412. PubMed ID: 36439185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and Concomitant Gut Microbiota and Endocannabinoidome Response to Diet-Induced Obesity in Mice.
    Lacroix S; Pechereau F; Leblanc N; Boubertakh B; Houde A; Martin C; Flamand N; Silvestri C; Raymond F; Di Marzo V; Veilleux A
    mSystems; 2019 Dec; 4(6):. PubMed ID: 31848310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional Viewpoint.
    Schiano Moriello A; Di Marzo V; Petrosino S
    Animals (Basel); 2022 Jan; 12(3):. PubMed ID: 35158670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of the endocannabinoidome-gut microbiome axis in eating disorders.
    Mir HD; Giorgini G; Di Marzo V
    Psychoneuroendocrinology; 2023 Aug; 154():106295. PubMed ID: 37229916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Important Role of the Endocannabinoid System and the Endocannabinoidome in Gut Health.
    Meletis C
    Altern Ther Health Med; 2019 Jun; 25(S2):24-28. PubMed ID: 31202201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders.
    Sihag J; Di Marzo V
    Lipids Health Dis; 2022 Jan; 21(1):9. PubMed ID: 35027074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulatory role of the endocannabinoidome in the pathophysiology of the gastrointestinal tract.
    Lian J; Casari I; Falasca M
    Pharmacol Res; 2022 Jan; 175():106025. PubMed ID: 34883211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocannabinoids--at the crossroads between the gut microbiota and host metabolism.
    Cani PD; Plovier H; Van Hul M; Geurts L; Delzenne NM; Druart C; Everard A
    Nat Rev Endocrinol; 2016 Mar; 12(3):133-43. PubMed ID: 26678807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. At the heart of microbial conversations: endocannabinoids and the microbiome in cardiometabolic risk.
    Khan RN; Maner-Smith K; A Owens J; Barbian ME; M Jones R; R Naudin C
    Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33896380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurobiological Processes Induced by Aerobic Exercise through the Endocannabinoidome.
    Forteza F; Giorgini G; Raymond F
    Cells; 2021 Apr; 10(4):. PubMed ID: 33920695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three of a Kind: Control of the Expression of Liver-Expressed Antimicrobial Peptide 2 (LEAP2) by the Endocannabinoidome and the Gut Microbiome.
    Shen M; Manca C; Suriano F; Nallabelli N; Pechereau F; Allam-Ndoul B; Iannotti FA; Flamand N; Veilleux A; Cani PD; Silvestri C; Di Marzo V
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus.
    Veilleux A; Di Marzo V; Silvestri C
    Curr Diab Rep; 2019 Nov; 19(11):117. PubMed ID: 31686231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoquercetin and inulin synergistically modulate the gut microbiome to prevent development of the metabolic syndrome in mice fed a high fat diet.
    Tan S; Caparros-Martin JA; Matthews VB; Koch H; O'Gara F; Croft KD; Ward NC
    Sci Rep; 2018 Jul; 8(1):10100. PubMed ID: 29973701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endocannabinoid system: an emerging key player in inflammation.
    Witkamp R; Meijerink J
    Curr Opin Clin Nutr Metab Care; 2014 Mar; 17(2):130-8. PubMed ID: 24419242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.
    Di Marzo V; Piscitelli F; Mechoulam R
    Handb Exp Pharmacol; 2011; (203):75-104. PubMed ID: 21484568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.